TRANSCRIPT 🔗
WEBVTT
00:00:01.000 --> 00:00:48.000
music music On the Mind & Matter podcast, we learn together from the best scientists and thinkers alive today about how your mind-body reacts to what you feed it. Before starting Mind & Matter, I spent 10 years in academia doing scientific research. I got a PhD in neuroscience from Harvard University, where I focused on neuroendocrinology and the neuroscience of behavior. And before that, I specialized in molecular, developmental, and evolutionary genetics.
00:00:48.000 --> 00:01:27.000
I use my scientific background to parse and translate the information guests share on the show, and in addition to the podcast, I write long-form content and send out a free weekly newsletter at themindandmattersubstack at mindandmatter.substack.com. I also offer private, science-based health consulting, where we work one-on-one and apply the same rigorous, evidence-first approach you hear on the podcast, the personalized, We can obtain and analyze your biomarkers, work on diet and behavior strategies, review supplements and drugs that you might be taking, or anything else related to general metabolic health. So, if you'd like more tailored guidance on your personal health, head to nickjacomis.com and fill out a short form or book time with me there.
00:01:27.000 --> 00:02:15.000
A great way to support my content in all of its forms is simply to visit mindandmatter.substack.com. You'll find a link to that in the episode description, and you'll also find a link to my current affiliate partners through my support page. These are products that I use myself that relate to physical, metabolic, or mental health. For example, one product I use every day is the Aqua True water filter, which removes heavy metals, microbes, endocrine disruptors, you name it, so that you have higher quality drinking water All of those links for health consulting, for my affiliate partners and the Substack page are all in the episode description. So thank you very much for listening and don't forget to check out mindandmatter.substack.com for all of my content. Thank you very much for joining me.
00:02:15.000 --> 00:02:16.000
Thank you. Nice to see you.
00:02:16.000 --> 00:02:20.000
Do you want to just tell everyone a little bit about who you are and what your background is?
00:02:20.000 --> 00:02:59.000
Yes, absolutely. I might give a little bit of a longer version so that it kind of introduces the field and what we're gonna be talking about today. So I did my PhD in Europe between Switzerland and France, and actually that's where I started to study lipid signaling network. In Switzerland, my PhD was more into the physiology, of lipid signaling and therefore it was about energy dependence and from cell types to cell types, neurons and glial cells.
00:02:59.000 --> 00:03:35.000
And then in France it was much more pharmacology and it was much more around how different stimuli will actually produce these lipid signaling. And it turns out that these lipids signaling I was studying is arachidonic acid, which is one of the constituents that formed the endocannabinoids. So it was a very opportunistic, a good foundation for me. And then what happens is that as I was getting ready to go to do my postdoc, The endocannabinoid field was starting.
00:03:35.000 --> 00:04:11.000
It was the very beginning. They had just discovered the first endocannabinoid, anandamide, which also has this arachidonic acid moiety. And I had the opportunity to go do my postdoc in San Diego with Daniele Piumelli, and I remember his question. He said, when we started, he said, you know, if there's one endocannabinoid, there's probably a second one, because we know that a lot of neurotransmitter systems and neuromodulators have multiple ligands and multiple receptors.
00:04:11.000 --> 00:04:38.000
So that's how I started into the endocannabinoid field during my postdoc. and it was very centered on 2-arachidonoylglycerol, again, the arachidonic acid moiety. And then, that was the very beginning, so we had so many fundamental questions to ask, how is it produced and everything where? And then I had the opportunity to start my lab, and I was really interested in trying to develop novel therapeutics.
00:04:39.000 --> 00:05:07.000
And you know, the field back then, the cannabinoid field, was very much focusing on studying the side effects, Memory impairment would be a really big one. But I was really interested in trying to figure out how, if there had any therapeutic potential for the endocannabinoids. So I started my lab in Seattle at the University of Washington in the School of Medicine. in 99, if I remember, 25 years ago.
00:05:08.000 --> 00:05:45.000
And then through all these years, what I've done is kind of navigate the field, trying to understand and identify the most promising therapeutic approach to target the cannabinoids. So initially, I was interested in neuroinflammation, so multiple sclerosis. Then I got really interested in seizure maintenance, especially with the effect of cannabidiol and the FDA approval. That was very promising, so I studied quite a bit of seizures and how endocannabinoids can actually modulate those seizures.
00:05:46.000 --> 00:06:17.000
And then more recently, when you want to develop a therapeutic approach, what you have to do is you have to think about the benefit, but you have to think about the side effects. What is the potential side effects of a therapeutic approach? So I've been really interested in trying to separate the side effects versus therapeutic effects of both THC and cannabidiol. And to do that, I might tell a little bit about the new technology that we're using to monitor these things.
00:06:17.000 --> 00:06:33.000
So that's what we're doing in my laboratory. As you can see, it's very broad. It's really, the goal is to find the most promising therapeutic approach and understand it at the molecular level so that we can go all the way to human clinical trials.
00:06:34.000 -->
Load full transcript
00:06:50.000
And so what are the endocannabinoids? You've already sort of hinted at the answer here. They're fatty molecules, and we'll maybe talk about where they come from and how they relate to diet and things like that. But just as a class of signaling molecules, what is the characteristic of endocannabinoids?
00:06:50.000 --> 00:06:51.000
What do they generally do?
00:06:52.000 --> 00:07:29.000
Well, endocannabinoids are really interesting and very special. They are actually quite different from most of the signaling mechanism that we have in the brain. You know, the field started with excitatory glutamate GABA inhibitors, and then the field got really interested, and when I say field is in neuroscience in general, going beyond these neurotransmitters and looking at neuromodulators. And that's when the field started discovering and working on serotonin, noradrenaline, dopamine, and then the opioids showed up.
00:07:29.000 --> 00:07:48.000
And then the opioids, you know, those are small peptides that modulates. And now we have yet another signaling mechanism, which is actually driven and carried by those lipid signaling molecules like the endocannabinoids. So they're very special. They're very different.
00:07:49.000 --> 00:08:09.000
than the other signaling mechanisms. And we can already say, we can start by emphasizing that there's two endocannabinoids. So how, like I mentioned before, there's anandamide, the first one, which means in Sanskrit, means inner bliss. Very appropriate name.
00:08:09.000 --> 00:08:39.000
And then there's a second one that I was involved in discovering, which is 2-AG. And even, I think the field now has really recognized that these two signaling endocannabinoids, anandamide on one side and 2-AG on the other side, are actually doing very different things in the brain and have very different functions, even though they're both endocannabinoids and they act on cannabinoids we're going to be focusing on the cannabinoid CB1 receptors in the brain.
00:08:41.000 --> 00:08:54.000
Got it. So there's a bunch of different stuff in the brain and body, different types of signaling molecules, different classes, different structures, different functions. Obviously they all have to be made out of something. Some of them are made out of things like amino acids and the building blocks of proteins.
00:08:55.000 --> 00:09:06.000
You mentioned, you know, the opioids are often peptides. They are basically little proteins. A lot of classic neurotransmitters or neuromodulators are basically amino acid like molecules. and so on and so forth.
00:09:07.000 --> 00:09:22.000
But the endocannabinoids are basically fat-derived molecules. They're pieces of fats that ultimately come from fats that we consume. So they're fatty substances. Where are they stored and where do they come from in our brain?
00:09:23.000 --> 00:09:32.000
When an endogenous cannabinoid is used by a neuron to signal something, to do something, where is the neuron getting it from, literally?
00:09:33.000 --> 00:09:56.000
Okay, so let's unpack this a little bit, because there's quite a bit of concepts here. It is true that endocannabinoids are lipids, and therefore where they reside is in the lipid bilayer of the membranes, for example. And those are what we call hydrophobic, so fat-preferring molecules. So they have a hard time going into solution into water.
00:09:57.000 --> 00:11:01.000
So they're mainly into the membrane. It is true that diet will influence the composition of the lipids, but it's not a direct relationship between I eat something fat and then I produce endocannabinoids. It's just the overall over time. I think we need to think about endocannabinoids, that these small lipids signaling molecules that are released from the membrane in an activity-dependent manner, the cell, there's actually two we can Emphasize already another difference or characteristic of the endocannabinoid signaling system is that some endocannabinoids are going to be produced in a tonic manner. They're going to be there all the time, whereas endocannabinoids can also be produced in an activity-dependent manner. on and off, just like neurotransmitter. I stimulate something and then I stop stimulating.
00:11:02.000 --> 00:11:11.000
So, endocannabinoids are produced on and off over seconds, very small time periods, but they can also accumulate for a very long time.
00:11:12.000 --> 00:11:54.000
No, I think that's important, right? So, when we say that these things are fat-derived and when we talk about certain fat-derived substances in the body, it's not that, you know, if I go eat a meal right now and I'm eating some fat and I'm putting it in my mouth and it goes into my stomach, it's not that those fat molecules literally get turned into endocannabinoids right now, right after I absorb it into my body, it's rather that those fatty acids get incorporated into membranes, into adipose tissue, maybe burned for energy, they get distributed throughout the membranes of my body. And then later on, they may or may not become things like endocannabinoids, but that will only happen if a relevant stimulus comes afterwards.
00:11:54.000 --> 00:11:54.000
Correct.
00:11:54.000 --> 00:12:08.000
What I eat is going to influence the fatty acid composition of my cells and my tissues. And what happens to me, the stimuli that are impinging on my body and what's happening internally, that will determine if and when those things later on get turned into endogenous cannabinoids.
00:12:08.000 --> 00:12:15.000
Correct. Absolutely. That's a very good description. So coming back to the idea of how are they produced?
00:12:16.000 --> 00:12:48.000
This is actually a very fascinating molecular machinery that's quite specific. So, there are several aspects to that. So, they are in the cell membrane, so they are lipids, and then we have enzymes that are going to cut those lipids, hydrolyze those lipids that are complex, and release smaller lipids that are
going to be the endocannabinoids. Those enzymes are going to be different if we're talking about the first endocannabinoid anandamide versus the second cannabinoid 2-AG.
00:12:49.000 --> 00:13:34.000
Yet another concept to emphasize that these two endocannabinoids are going to be produced under different conditions by enzyme number one which is NAPLD for anandamide, and enzyme number two, which is daglycase for 2-AG. So two different enzymatic pathway are going to release those lipids from the membranes. So that's already important to emphasize. Because lipids do not like to interact with water, there's actually very recent studies studies that have discovered some mechanism by which you can actually shuttle these lipids from one cell to the other.
00:13:34.000 --> 00:14:11.000
Because from one cell, it needs to go through the cytosol, which is hydrophilic water. So it needs something to help it. And I know you had Steve Laviolette that actually interviewed, and he talked about the fatty acid binding proteins. So those are actually really fundamental mechanism by which these proteins that have hydrophobic greasy pockets The endocannabinoids are gonna go into this greasy pocket of the protein, and like that, there's gonna be a shuttle that's gonna bring this endocannabinoid from one cell to the other.
00:14:11.000 --> 00:14:42.000
Now let's go deeper, let's double-click on the cell itself. You can actually have endocannabinoids that are released from the plasma membrane, and then they will go intracellularly, because there's also some intracellular receptors, and they're gonna be doing a lot of things. You had You interviewed Giovanni Marzicano, so he discovered the cannabinoid CB1 receptors on mitochondria. So now we're talking about an intracellular signaling pathway.
00:14:43.000 --> 00:15:11.000
where endocannabinoids are produced from the plasma membrane, needs to go intracellularly and the shuttle is also gonna be a fatty acid binding protein. So that's one mechanism that is actually very special. There's no other signaling mechanism that uses these shuttles. And this is actually really important because we'll probably talk about this, we will become a very important and interesting therapeutic target, those fatty acid proteins.
00:15:12.000 --> 00:15:53.000
The second mechanism that has been recently discovered, because the question is, since these lipids do not like to interact with water, how are they going from one cell to the other? I mean glutamate, GABA, dopamine, it's easy, they're hydrophilic, they just go through water. But in the endocannabinoids, so there's actually new research that's shown that in an activity-dependent matter, again, the cell actually releases these extracellular microvesicles, tiny vesicles of lipid that are fascinating because they actually travel from one cell to the other, and they contain inside quite a bit of information. They might even have mRNA.
00:15:54.000 --> 00:16:17.000
that will actually change the phenotype from the next cell. But they also have, because they're micro-physical, they have a composition of their lipids. that is very specific and it turns out that they actually accumulate endocannabinoids. So now you have a packet of endocannabinoids that goes from one cell to the other, fuses with the next membrane.
00:16:17.000 --> 00:16:43.000
You have more endocannabinoids in the next cell and therefore the cannabinoid receptors are gonna be activated. So that's how endocannabinoids are thought to travel from one cell to the other via those fatty acid binding protein or microvesicles. or intracellularly also via those endo fatty acid binding proteins. So those are very different and unique mechanism.
00:16:43.000 --> 00:17:25.000
Yeah. So these endocannabinoids, they are lipid molecules, they are little pieces of fat, and basically there are shuttles. So you can quite literally think of this almost like a city planner, like there's buses. Like like shuttles like a protein has a water soluble end and a fat soluble end and a greasy molecule a lipid like an endocannabinoid can get onto the shuttle and be shuttled from one cell to a completely different cell or within a cell from one place to another such as from the outer membrane to the mitochondria and so there's these little shuttles moving all over in different cells, moving these greasy molecules around to and from all of the different membranes on the outer side of the cell and even within the cell in places like the mitochondrial membrane.
00:17:26.000 --> 00:18:05.000
Absolutely, and the trafficking map is actually a really good analogy because you have, I don't know, I think we already have like 10 different fatty acid binding proteins. They're gonna have different abilities to transport either anandamide versus 2-AG, so there's another difference. There might be different shuttling mechanisms for anandamide versus 2AG that go at different speed. And all of this tight regulation of anandamide versus 2AG signaling is going to determine how much of the endocannabinoid is going to activate the cannabinoid receptor and where.
00:18:06.000 --> 00:18:17.000
And what are these receptors? Let's go through them one at a time. So the main one, cannabinoid receptor one, what kind of receptor is it? How common is it?
00:18:17.000 --> 00:18:25.000
Where is it? Is it mostly in the cell membrane? Is it mostly in mitochondria? Is this in very specific parts of the brain or is this something that's all over the place?
00:18:26.000 --> 00:18:49.000
Yes, so the cannabinoid CB1 receptor is what we call the G-protein coupled receptor. So it's part of the family of those receptors that are typically modulated, for example, dopamine, serotonin. So it's a modulator receptor called G-protein coupled receptor. So it's gonna modulate cellular activity.
00:18:50.000 --> 00:19:07.000
The... Pretty much, let's go at each level. So at the molecular level, what it does is where is it expressed is actually very
important. So cannabinoid CB1 receptors are predominantly expressed presynaptically on neurons.
00:19:08.000 --> 00:19:17.000
And what they do there is they regulate neurotransmitter release, and they are typically inhibitors. of neurotransmitter release.
00:19:18.000 --> 00:19:36.000
So in other words, what you're saying is at the point of contact between two neurons, the first neuron is sending a signal to the second neuron. The second neuron is receiving that signal from the first neuron. The first neuron, the one sending the general neurotransmitter signal, that's the one where the CD1 receptor will generally be.
00:19:40.000 --> 00:19:48.000
So let's start again. So we have a neuron number one, which we're gonna be calling the postsynaptic neuron.
00:19:48.000 --> 00:19:52.000
Okay, so yeah, you're saying postsynaptic is number one, the receiver of the message.
00:19:52.000 --> 00:20:17.000
Correct, the receiver of the message. And then what it's going to do is the endocannabinoid is gonna go back to the presynaptic. and say slow down, that's enough, shut off, which is why the endocannabinoids are considered retrograde, so from postsynaptic to presynaptic inhibitors of transmission because they slow down transmission. That's enough glutamate.
00:20:18.000 --> 00:20:23.000
Endocannabinoids come on CB1 receptors and reduce glutamate release.
00:20:25.000 --> 00:20:37.000
Yeah, so if a neuron's getting too much input, or it's gotten enough input already, it's sending a signal back in the form of an endocannabinoid to the neuron, giving it that input, and it's saying, that's enough, no more needed.
00:20:38.000 --> 00:20:55.000
Feedback, that's enough negative, absolutely. And actually, so now let's go, so that's at the subcellular level, and that's the most predominant is CB1 receptor. There's a couple of more locations where CB1 receptors are expressed. We already mentioned on mitochondria.
00:20:56.000 --> 00:21:17.000
So that's the intracellular CB1 receptor, and there its function is going to be to regulate mitochondrial function. And mitochondria does many things, including producing energy and substrates. So CB1 receptor has a role in regulating how much energy the cell will utilize. And then there's also...
00:21:18.000 --> 00:22:06.000
although much less studied, there's also some CB1 receptors on the soma, like on the main cell. And there they have a slightly different function according to the initial results is that there they will actually signal all the way to the nucleus and change the phenotype of the neuron. And that's actually another very predominant role of the endocannabinoid signaling system is to regulate the phenotype of the neuron, what kind of neurons are we going to have and where are they actually connecting? Because CB1 receptors, I believe, is already expressed at the stage two cell after, like, you know, really at the very beginning.
00:22:06.000 --> 00:22:26.000
And actually the CB1 receptors regulate cell proliferation and cell migration. So the endocannabinoid signaling system, these lipids, when they activate and interact with the CB1 receptor during development, they'll actually regulate the phenotype of the neuron.
00:22:27.000 --> 00:22:35.000
Yeah, yeah. So these things are very, very involved in not just what mature neurons are doing, but actually in the development and the setting up of cells and circuits itself.
00:22:36.000 --> 00:23:16.000
Correct. Which is why this is a good moment to say, which is why it's a major concern about adolescent consuming THC, because now the THC is going to flood the brain that is still developing and all the CB1 receptors are going to be interacting with THC instead of having a very precise directed endocannabinoid that tells the CB1 receptor go this way. So this is one of the hypothesis of cannabis use disorder is when adolescents are consuming THC.
00:23:16.000 --> 00:23:51.000
THC is activating all these neurons and therefore the wiring of those neurons is not precise enough anymore because instead of following the endocannabinoids, the CB1 receptors are flooded with THC. And to the most vulnerable adolescent, this could actually It results in cannabis use disorder, but some of these patients actually have schizophrenic episodes, psychotic episodes, because of these neurons that have been miswired.
00:23:52.000 --> 00:24:10.000
And so when an endogenous cannabinoid, such as an andamine, gets used for signaling purposes, so it's this little fatty substance that ultimately comes from fatty acids in the cell membrane, how exactly is the cell producing it? Is it literally clipping off a piece of the cell membrane?
00:24:10.000 --> 00:24:26.000
Correct, yeah. Yes, it's clipping off a subunit, a small piece of... Imagine the... The plasma membrane has a bunch of Legos and then it's taking off one of the Legos and it's cutting it off and giving it to the next cell.
00:24:27.000 --> 00:25:10.000
Absolutely. One thing that's really interesting to think about in the dichotomy between anandamide and 2-AG, now the field is realizing how different these small molecules, there's just a new paper that just came out by a very predominant lab, showing that different behaviors, so now we're actually able to, this might be a good time to actually introduce the new tools we have to actually study endocannabinoids. So there's actually new technology that came up from some labs that are allowed to sense or detect endocannabinoids production in mouse brain in real time.
00:25:10.000 --> 00:25:51.000
And basically the technology is based on the cannabinoid CB1 receptor. And then in the intracellular part of the CB1 receptor, instead of having that G protein that does the signal transduction, they attach the fluorescent green protein, GFP. And now each time the endocannabinoid hits that sensor, the green protein flashes a green fluorescence. So now we're actually able to take these sensors, which are proteins, virally infect
some mouse brains so that these sensors are expressed in specific neurons or specific brain areas.
00:25:52.000 --> 00:26:33.000
And now when a little mouse goes and does its little behavior, we can actually see in real time endocannabinoids being produced. You have no idea the the emotion I had the first time I saw that sensor go up and down in real time from a molecule that I discovered during my postdoc 25 years ago, you know, in a tube, and now I see that molecule being produced in real time in a mouse. So now let's come back to, now that we know that we have this new tool to sense endocannabinoids, And there's tools that can sense either the first endocannabinoids, anandamide, or the second endocannabinoids, 2-AG.
00:26:33.000 --> 00:27:15.000
And now we know that actually different behaviors will produce one endocannabinoid versus the other. A very novel concept. For example, aversive stimuli, something that will create fear, like shocking, an electrical shock for a little mouse, that will actually create endocannabinoid 2AG, as detected by the sensor. By contrast, if you give a psychoactive drug, for example, nicotine or cocaine or ethanol, these psychoactive drugs are also going to produce endogenous cannabinoids, but with different dynamics.
00:27:15.000 --> 00:27:46.000
Some of them will produce more anandamide, some of them will produce more 2-AG. And therefore now the field is starting to realize that these different behaviors and these different stimuli differentially activate endocannabinoids, anandamide versus 2-AG, and therefore most likely different cellular responses. different CB1 activation on different cell types, depending on the brain area. So that's where the field is at now.
00:27:46.000 --> 00:27:59.000
We're trying to understand how endocannabinoids are related to different behaviors and different stimuli so that we can actually foster that and maybe develop novel therapeutics.
00:28:03.000 --> 00:28:29.000
So people often say that Endocannabinoids are use dependent or they're made on demand. So there's mechanisms that allow the cell to say, OK, we need some endogenous cannabinoid right now. We can pull some from the membrane and use it right now for whatever the stimulus that's calling for it is. And so what are the main signals that start to determine when and where and how much of these things are made?
00:28:30.000 --> 00:28:39.000
Are these things highly dynamic? Can different stimuli drive very different levels of production? And give us a sense for the dynamics here.
00:28:40.000 --> 00:28:48.000
Absolutely. It's a great question. And we're at the cutting edge of science right now. These are actually the kind of questions that the fields are asking.
00:28:49.000 --> 00:29:25.000
So, these endocannabinoids are produced by different enzymes, so it will really depend on where that enzyme is located in the cell, in the subcellular compartment. So, if this enzyme is only in cell type 1, For example, the enzyme that produces anandamide, NAPE-PLD, will be expressed only in neurons A. And by contrast, neuron B will only express the diglyphase, which produces the second endocannabinoid, 2AG. You already there have a dichotomy of one cell versus the other.
00:29:25.000 --> 00:29:44.000
Got it. So depending on the concentration and pattern of proteins, such as these enzymes in any given neuron, it can determine the cocktail of cannabinoids that might be produced. One neuron might produce only anandamide, or it might produce only 2-AG, or it might produce a combination.
00:29:45.000 --> 00:29:52.000
That's correct. Absolutely. And that's the first level. So the enzymatic activity that produces the lipid.
00:29:53.000 --> 00:30:26.000
So now how are we going to regulate the enzymatic activity? It turns out that most of these enzymes are actually calcium dependent. Calcium is a fundamental signal transduction mechanism in cells, that when a neuron, let's focus on neuron, when a neuron is activated, when it's depolarized, you have this influx of calcium that gets into the neuron, and that rise in intracellular calcium then will go and activate multiple enzymes, including enzyme that will produce the endocannabinoids.
00:30:26.000 --> 00:30:58.000
So that's the second level of regulation let's say of endocannabinoid one the first one is where is the enzyme the second one is how much calcium is reaching that enzyme, and actually for how long? So that's the third level of regulation. So now let's stimulate the neurons with two different types of receptors. One receptor that will be on and off very quickly, or even three receptors.
00:30:58.000 --> 00:31:37.000
One that's on and off very quickly, one that goes on for minutes, and one that goes on for hours. like a glutamate metapotropic receptor for minutes, and NMDA receptors for almost, you know, for plasticity. So then you'll have the third level of regulation, which is, does this neuron express this receptor, nicotinic and NMDA? And for how long is that receptor going to be activated, which will result in the increase in calcium, which will activate the enzyme that will release endocannabinoid.
00:31:37.000 --> 00:32:22.000
And for the non-neurobiology people that listen to this, One of the things to connect here is when neurons are active, depending on how much they're active, the pattern they're active with, depending on the ion channels they have, calcium is tied to that activity. So when the neurons are active, some ion channels allow calcium to come in. And so The important piece here is that some of these enzymes that produce endocannabinoids are calcium dependent. And so what that means is the level of activity, the pattern of activity that a given neuron is experiencing is going to determine then the pattern of endocannabinoids it makes because calcium is sort of the dot that connects the enzymes that make the endocannabinoid to the activity levels that neuron is experiencing overall.
00:32:23.000 -->
00:32:35.000
Absolutely. Now let's go to the other end of the signaling network. So we've produced the endocannabinoids now in an activity dependent manner. These endocannabinoids are gonna activate specific receptors.
00:32:36.000 --> 00:33:07.000
And now we need to talk about how we're gonna stop that signal with enzyme that actually inactivate those endocannabinoids. So there's another here, very nice diversity of enzyme that are going to stop endocannabinoid signaling. For anandamide, we have this enzyme which is called FA, which is a fascinating enzyme. So each time anandamide is produced and activates the CB1 receptor, then it unbinds the CB1 receptor and it's inactivated or hydrolyzed by FA.
00:33:07.000 --> 00:33:34.000
So that's the first endocannabinoid. And then we have another mechanism for the second endocannabinoid, 2AG. 2AG is produced, activates the CB1 receptor, and then it's actually hydrolyzed or inactivated by two different enzymes that are expressed in two different parts of the cells, most likely because they have different functions. So, the most famous one is monoacylglycerol lipase, MAG-lipase.
00:33:34.000 --> 00:33:59.000
This enzyme that hydrolyzes and inactivates 2AG is expressed close to the CB1 receptor in the presynaptic terminal. That means that MAG-lipase is really regulating the amount of endocannabinoid 2AG at the level of the target. There's a second enzyme close to the CB1 receptor. There's a second enzyme, which is actually postsynaptic, ABHD6.
00:34:00.000 --> 00:34:14.000
And that enzyme hydrolyzes 2EG, where 2EG is produced postsynaptically. So you can see how these enzymatic pathway from one cell to the other are gonna regulate the signaling network very precisely.
00:34:14.000 --> 00:34:37.000
Yeah, so the production of endocannabinoids from the fatty cell membrane is coupled to the activity of a neuron. How active it is is going to be related to how much calcium comes in. That determines how much these enzymes start clipping the membrane to make endocannabinoids, and then those get deployed. And then there's another set of enzymes that basically turn off the signal and get rid of those endocannabinoids.
00:34:38.000 --> 00:34:58.000
So what all of this basically means is on both ends, you've got enzymes, you've got protein-based regulation that allows you to have pretty precise spatial and temporal regulation of this endocannabinoid signal. The cell can turn on and turn off the signal in very particular locations on demand as it's needed.
00:34:58.000 --> 00:35:20.000
Correct. It's very similar to other neurotransmitter and neuromodulator systems. Glutamate is produced in an activity-dependent manner, and then it's removed from the synaptic cleft by a transport mechanism. Noradrenaline is produced, and then there's an enzyme that, or even an uptake system that removes it.
00:35:21.000 --> 00:35:46.000
So, the signaling system in the brain is always an on-off. You need to produce, activate the receptor
and stop. And the endocannabinoids, that's how they do it. There's another aspect that's really fascinating in lipid signaling is that actually these lipids, when I say that the enzyme is going to inactivate these endocannabinoids, that is correct.
00:35:46.000 --> 00:36:04.000
That means that for, let's take the example of, 2-AG. So let's take 2-AG. So 2-AG is arachidonic acid, the fatty acid, and then there's glycerol. The enzyme, what it's going to do is gonna cut this lipid and then release arachidonic acid.
00:36:05.000 --> 00:36:17.000
Therefore, it's not an endocannabinoid anymore. But now it's arachidonic acid. Arachidonic acid is very bioactive. It will actually produce prostaglandins and be involved in inflammation.
00:36:19.000 --> 00:36:31.000
Now, let's go before endocannabinoids. Diacylglycerol is the precursor of 2AG. Diacylglycerol is actually bioactive also. It regulates protein kinases.
00:36:31.000 --> 00:36:59.000
So, the way to think about these lipids signaling is fascinating because there's multiple As a lipid is transformed into another lipid, it becomes something else. Before an endocannabinoid, it regulates kinase, then an enzyme changes it, it becomes an endocannabinoid, it activates cannabinoid receptor. Then another enzyme changes it, it becomes arachidonic acid, and now it's involved in inflammation.
00:36:59.000 --> 00:37:21.000
So you can have a piece of a cell membrane and it becomes another type of lipid and then another type of lipid and then another type, but they're not merely intermediates. At each step, that molecule is now a new molecule that does something. And so it becomes very important now to think about, well, how many steps are there, but also how long do you spend at each step?
00:37:21.000 --> 00:37:28.000
Correct. Yeah. And therapeutically, when you block one enzyme, you're not going to only block one thing. What happens?
00:37:28.000 --> 00:37:32.000
You're blocking the next step, too. Right. You have to think about those things.
00:37:32.000 --> 00:37:48.000
Yeah. And this will probably tie into why, you know, as I'm sure we'll get to why designing drugs and designing therapies isn't as easy as we might conceptually like to think, because it's not just this one thing does one thing. Lots of things are pleiotropic. They do multiple things.
00:37:48.000 --> 00:37:57.000
They can turn into another thing very quickly. And there's regulation at all of these steps. And it's complex, literally complex. Absolutely.
00:37:57.000 --> 00:38:35.000
And it moves all the time. So, how do we start to think about the way that the fatty acid composition, the overall fatty acid composition of our membranes and our neurons or anywhere else relates to the overall pattern of signaling molecules get produced, including cannabinoids? And how do we think about how that relates to things like our pattern of dietary fatty acid intake? So, if I start eating a different level of polyunsaturated fat in my diet tomorrow, and
I continue doing that for weeks and weeks, is that meaningfully gonna shift the membrane composition of the fatty acids in my neurons ultimately?
00:38:36.000 --> 00:38:42.000
And is that gonna in turn affect sort of the overall levels or the dynamics of things like endocannabinoid signaling?
00:38:43.000 --> 00:38:56.000
I think there's some initial evidence that that might be the case, but I would say that's probably not the case. the main molecular mechanism that regulates the endocannabinoid signaling system.
00:38:58.000 --> 00:39:18.000
And so let's talk about, well, I guess let's just focus on anandamide and 2AG separately and together, but let's just take them one at a time. How similar are they exactly? And then what are the differences in terms of their actual structure and then the general functional differences that they tend to have?
00:39:20.000 --> 00:39:49.000
So the chemical structure is similar at one level, like this fatty lipid, the fatty portion of these endocannabinoids is the same. They both have arachidonic acid. And there's a little piece of additional, molecule to arachidonic acid. In anandamide, it's ethanolamine, so it's a small, and then in 2-Ag, it's arachidonic glycerol.
00:39:49.000 --> 00:40:28.000
That little piece of molecule at the tip of arachidonic acid is what is going to clearly differentiate anandamide from 2-Ag. because they have the same arachidonic acid moiety. That little piece of molecule will make a big difference in the way the endocannabinoids are interacting, binding, with stimulating the cannabinoid CB1 receptor. Here's another very big difference between anandamide and 2-AG, is that anandamide, as it interacts with the cannabinoid receptor, it's only able to partially activate to the CB1 receptor.
00:40:30.000 --> 00:40:59.000
which is actually very similar to what THC does. THC is a partial agonist. It doesn't completely stimulate CB1 receptor, which is probably why it stayed around, because if you completely, fully stimulate CB1 receptor, you become cataleptic, way too strong. By contrast, endocannabinoid 2AG, the second one there is actually a full agonist at the endocannabinoid CB1 receptor.
00:40:59.000 --> 00:41:06.000
So that's another difference. Partial activation, anandamide, full activation, 2AG.
00:41:06.000 --> 00:41:20.000
Yeah, yeah. And this would actually correspond to, so activation of the CB1 receptor actually has an inhibitory effect on a neuron. So partial versus full activation would then correspond to a somewhat decreasing activity versus more strongly decreasing activity.
00:41:20.000 --> 00:41:47.000
Correct. So now let's actually look a little bit further in the difference also when we compare to THC. Because when somebody consumes or inhales THC, THC is going to flood the brain and therefore activates CB1 receptor everywhere that it finds it. Whereas endocannabinoids are going to be produced in an activity-dependent manner physiologically where it's supposed to be.
00:41:48.000 --> 00:42:09.000
That's their role. The best example I have is they're going to be produced when I go for a jog because it's hurting, right? So, it's going to be actually controlling my pain. and I'm a Neanderthal and being, you know, a T-Rex is behind me, I need to continue even though it hurts so that I can survive.
00:42:10.000 --> 00:42:44.000
So endocannabinoids are actually also very parallel to the endorphins, the opioid system, which also are endogenous painkillers. So that's how one can actually think about the big difference between THC activating all the neurons and inducing psychotropic effects, the high, versus endocannabinoids being produced exactly where they're supposed to be produced, and therefore we don't get high because these endocannabinoids are just doing what they're supposed to do, which is, for example, regulate pain.
00:42:47.000 --> 00:43:19.000
people often ask this type of question or they have of me in the past where it's like, why aren't we high all the time if we're filled with endogenous cannabinoids? But basically what you're saying is, you might have one synapse in one part of your brain that needs more anandamide and it cooks it up right then and there. That's not going to affect how much gets made at some other synapse in another neuron. It's this point to point synapse by synapse regulation of these things, whereas when you consume an exogenous cannabinoid like THC, you're now putting it into your bloodstream and it's kind of flooding everywhere and hitting receptors all over the place all at once.
00:43:20.000 --> 00:43:40.000
Absolutely. Here's an interesting example that I think about sometimes is in the hippocampus, so this part of the brain that's involved in memory formation consolidation. There's quite a bit of CB1 receptors that are there. So what is the role of the cannabinoid CB1 receptor in the hippocampus?
00:43:41.000 --> 00:44:06.000
Well, let's think about what happens when somebody takes so much THC all the time during adolescence. One of the first impairment is memory impairment for people that consume THC. They forget things. their energy level might not be as high.
00:44:07.000 --> 00:44:30.000
That's because the THC is actually activating all these CB1 receptors in the hippocampus and is messing up the memory formation. Now, what is the role of the endocannabinoids in the hippocampus? Well, during a day, I think My hobby is photography, so I kind of hear about that sometimes. During a day, we see about 2,000 pictures.
00:44:36.000 --> 00:44:44.000
But we don't want to remember everything. I want to remember you. I want to remember how you look. So I'm going to consolidate that.
00:44:44.000 --> 00:44:56.000
My noradrenaline is going to take that memory and consolidate that. But there's many things that happened today that I saw that I don't want to remember. I don't need it. And the idea is that the endocannabinoids are going to go.
00:44:57.000 --> 00:45:11.000
and eliminate
this memory. I don't need it. I don't need to remember everything. So endocannabinoids could actually remove some selective memory, which is why the side effect of THC is memory impairment.
00:45:12.000 --> 00:45:26.000
Yeah. And that's, you know, it's always important to remember that memory The flip side of remembering is forgetting. You need both things in order for the memory and the memory consolidation to actually be functional. You simply can't and don't want to remember every detail of everything.
00:45:26.000 --> 00:45:27.000
That's actually going to be an impairment.
00:45:28.000 --> 00:45:51.000
Correct. Which brings us to post-traumatic stress disorder. all the individuals that have such strong fears that they actually have a hard time to forget. And one of the idea is that by using the self-medicate with THC to maybe forget those memories that are so hard to remember.
00:45:52.000 --> 00:46:11.000
Yeah, yeah. And people, I mean, people often talk about cannabis and cannabinoids in the context of PTSD. Maybe someone like a veteran has these traumatic memories. The idea is, right, you have the memory, you have the episodic memory, like you remember what happened, but the emotional power is sticking with you.
00:46:11.000 --> 00:46:29.000
You actually want to kind of forget or dampen that component. And the failure to forget that, so to speak, is what the PTSD is in some sense. And so, the idea would be, well, how do you actually dampen the emotional salience of the memory? And perhaps cannabinoids are one way to do that.
00:46:29.000 --> 00:46:45.000
Could be one way to do that. The memory was so salient that were so much nor adrenaline, it was so stressful that it was consolidated and remembered. And there was not enough endocannabinoids to forget it. And therefore you have post-traumatic stress disorder.
00:46:47.000 --> 00:47:09.000
The issue with treating with THC is that it has a very tight, narrow therapeutic window. It might have some medical properties, but it will have some side effects. And therefore really it's a decision medical decision with the doctor usually to be able to find a good regimen Well, so how do we think about how do we think about things?
00:47:09.000 --> 00:47:28.000
You know, we've already said that This endocannabinoid system the system of endocannabinoids receptors and so forth. It's ubiquitous. It's all over the brain It's not like in one part And it's spatially and temporally specific, right? Sort of a point-to-point regulation to this.
00:47:28.000 --> 00:47:48.000
You can use it in a synapse-specific manner. Given that someone with PTSD, let's say they have a traumatic memory that is bothering them and causing them issues in their lives. You want to dampen the emotional salience of that memory that they're failing to forget, so to speak. But you don't want to interfere with memory consolidation generally.
00:47:49.000 --> 00:48:08.000
You don't want to disrupt other memories in their brain. How do you start to think about playing with this endocannabinoid system so that you're going to selectively help with the forgetting and the remembering in the one circuit that's problematic, or I should say the one memory engram that's problematic, without scrambling memory or disrupting memory more generally?
00:48:08.000 --> 00:48:30.000
Absolutely. That's where actually the small molecules or medicine that will modulate the endocannabinoid signaling enzymes might come in. The big difference again, between the THC that is going to activate all the receptors throughout the brain. And actually let's have one little precision.
00:48:30.000 --> 00:48:56.000
Not every neuron in the brain expresses CB1 receptor. There are some, There are some neuronal population that don't. And one of the most salient one to think about is the dopaminergic neurons from the VTA. And therefore, even though there is actually a drug addiction component to cannabinoids, and then cannabinoids increase dopamine, right?
00:48:56.000 --> 00:49:08.000
It's pleasurable. There's an addiction. Actually, those dopamine neurons do not express CB1 receptors. The other ones close to the dopamine neurons that regulate dopamine neurons.
00:49:08.000 --> 00:49:32.000
that stimulate dopamine production. But coming back to what you were saying, I think that's where the field has a lot of promises is to actually target the enzyme that regulate the endocannabinoid signaling system instead of stimulating all the receptors. Because, for example, for memory, memory is actually a process. You have your short-term memory and then you have your long-term memory.
00:49:33.000 --> 00:50:14.000
So one, It would be an interesting testing to do would be to actually provide, give some inhibitors of the enzyme that inactivate the endocannabinoids. So if I take an inhibitor of that enzyme, I'm gonna have more endocannabinoids that are gonna accumulate, and therefore maybe it'll help me forget. And I'll do it in a very specific time period where I have the short-term memory And therefore, that short-term memory is gone, and it's not sent to the long-term memory and consolidated. That would be one way.
00:50:14.000 --> 00:50:14.000
Yeah.
00:50:15.000 --> 00:50:53.000
And I guess if I play with this a little bit, the way that I'm imagining that would go would be... If we remember the fact that memories are consolidated and reconsolidated, every time we recall things, the memory sort of becomes a little bit more labile and can be changed, can be weakened, strengthened, changed in different ways. I guess the idea here might be that if you have someone with PTSD, say, they've got a traumatic memory, they're failing to dampen that memory, to forget the emotional intensity of it. You might have them, say, take a therapeutic, like an endocannabinoid-based therapeutic, specifically when they're recalling that memory, but not all of the time.
00:50:54.000 --> 00:50:59.000
And that might help it sort of be dampened down
or forgotten, at least to some extent.
00:50:59.000 --> 00:51:02.000
Absolutely. That would be nice. It'd be nice to try.
00:51:03.000 --> 00:51:20.000
Now, how much of this is... theoretical, like these ideas kind of all fit together in a conceptually nice way, but have we seen much success with developing things like endocannabinoid enzyme inhibitors to actually show these kinds of benefits? Is that something people are working on today?
00:51:22.000 --> 00:51:41.000
That's a good question. There's a lot of hypotheses out there, very little theory. Theory will become, that's when we have something that's written in the textbook and we know it works like that. We have a lot of hypothesis and we are gonna be testing that it's working like this.
00:51:42.000 --> 00:52:31.000
So now this might be a good place to start talking about preclinical testing of novel endocannabinoid therapeutics. So, The cannabinoid field is actually quite young as compared to the opioid field because we only discovered in the 90s the endocannabinoids and the receptor compared to the opioids, for example. So we know much less on the endocannabinoid signaling system compared to the opioid signaling system. So there is, and then there's also, there's been some challenges to do preclinical research in the cannabinoid, not much funding, and also the schedule one limitation to have access to THC.
00:52:32.000 --> 00:53:06.000
All of this has really slowed down the field to make progress. Now things are a little bit better, so there's actually much more that we understand. So the preclinical field now, and we have the tools also to actually do some nice thorough preclinical testing. So the field is actually now testing multiple things, multiple therapeutic indication if we either The most logical one to start with is the one that we talked about, is to target the enzyme that degrade endocannabinoids.
00:53:06.000 --> 00:53:30.000
Just so people are clear, there's enzymes that naturally degrade endocannabinoids when they're released. So they're controlling sort of when the signal gets turned off. One of the things that is attractive about making that a therapeutic target is you can regulate how much of the endocannabinoid signal there is, but still maintain sort of the natural patterns of endocannabinoid production.
00:53:31.000 --> 00:53:37.000
Only where they're produced physiologically, you make it stronger. Absolutely. Absolutely. So there are some...
00:53:39.000 --> 00:54:11.000
There's some things that, so we're gonna be talking mainly about two enzymes. We're gonna be talking about FA, the fatty acid amidohydrolyzed that inactivates anandamide, endocannabinoid number one. And then we're gonna be talking about MAG-LIPASE, monoacetylglycerol lipase that inactivates the second endocannabinoid 2-AG. So the first one targeting the fatty acid amidohydrolyzed, unfortunately the, the field went, in my opinion, a little bit too fast in two humans.
00:54:12.000 --> 00:54:37.000
We
didn't really have enough information. The two limits There's two critical things that you have to think about when you develop a new therapeutic approach. One, you have to make sure that your molecule, your new medicine, is gonna do the job that you expect. It's gonna go and inhibit fatty acid aminohydrase only, and not do something else that could be toxic.
00:54:38.000 --> 00:55:12.000
The second challenge is to actually find the actual disease that we're gonna try to temper or even cure. And that's where the preclinical testing in our little mice, we have mice models of different diseases. And therefore what we're gonna be doing the field is to take that fine inhibitor and test it in our little mouse for certain indication. What is it for pain, for anxiety, fear, anxiety, for depression, all these indications.
00:55:14.000 --> 00:55:34.000
Unfortunately, there was actually a first molecule that was a fine inhibitor that went into a human clinical trial in Europe. And unfortunately, that clinical trial, or fortunately, was stopped right away because of tremendous side effects. Tremendous side effects.
00:55:34.000 --> 00:55:35.000
What were they?
00:55:37.000 --> 00:55:54.000
I believe there were some patients that were even considered brain dead. They had no more neuronal activity in their brain. A handful, obviously, when you have that kind of side effect, you stop the clinical trial right away. Right.
00:55:54.000 --> 00:56:05.000
And I guess, so the idea here, right, if it's a PHA inhibitor, you're inhibiting the enzyme that degrades anandamide. So you would expect to have more anandamide generally, which means more inhibition of neural activity.
00:56:06.000 --> 00:56:35.000
And basically you're saying, if you take that to the extreme, you basically get... Well, actually, so there's a second part to this story. which is what I said first, is you need to make sure that your molecule is clean and it's doing what it's supposed to do. And what was discovered a couple years later in a science paper by my colleague Mario van der Stelt, he actually, how would you say, he profiled that molecule.
00:56:35.000 --> 00:57:03.000
He looked at what are the other proteins that are inhibited by this inhibitor that we thought were specific to pho. And he found this other protein, I forget what the name was, but it was a critical protein involved in neuronal viability. And therefore, this first molecule, unfortunately, that was given into humans, stopped the clinical trial right away. The entire field freaked out.
00:57:04.000 --> 00:57:15.000
Obviously, this is a bad therapeutic approach. But then now we understand it's probably an okay therapeutic approach if you have the right molecule that only inhibits FAL.
00:57:16.000 --> 00:57:29.000
Yeah. So for some reason, people thought this was a specific pha inhibitor, an inhibitor of just this enzyme, but it wasn't. How does that like, is that an easy thing to miss? Or was this just like a weird case?
00:57:29.000 --> 00:57:31.000
Why was it thought that this was specific?
00:57:32.000 --> 00:57:55.000
I wish I was on the field to understand the details. But in drug development, that is a really big component that you do up front, is you kinda look at what are the off targets, what are the other proteins. Typically what we do is we look at the off targets, the proteins that are critical for life. Some proteins in the heart.
00:57:56.000 --> 00:58:13.000
Don't give this molecule because you're gonna have a heart attack. That we know right away. I think this was a more, less understood enzyme that was targeted by this molecule. And therefore it was not on the radar.
00:58:13.000 --> 00:58:28.000
People were not thinking about it. And it's only when Mario did this unbiased approach that he discovered, oh no, there's this enzyme. So now obviously we know molecules should not target that enzyme. They're going to be brain dead.
00:58:29.000 --> 00:58:46.000
And I guess that's one of the strengths of being able to do unbiased approaches in preclinical animal models is you don't have, you know, there's known unknowns, there's unknown unknowns. These unbiased approaches allow you to sort of see everything even if you don't already know something about it.
00:58:47.000 --> 00:59:06.000
Correct. So that's the story of the inhibition of pha. I think the field is still working on it and trying to have cleaner, more selective by inhibitors, and maybe find the right indication. What are we going to try to cure anxiety?
00:59:06.000 --> 00:59:38.000
And so, and now that we know in our little mice that different endocannabinoids do different things, that might help the field to find the right indication. And now there's other really promising therapeutic approaches that now are moving forward. based on preclinical evidence and cleaner molecules, and they're targeting the monoacylglycerol lipase, the second enzyme that regulates 2AG. And those are moving forward nicely.
00:59:38.000 --> 01:00:00.000
There's multiple indications, including anxiety and addiction. And I believe they're already in phase two human clinical trials, which means that their toxicity level it's pretty good. There's not much side effects if they're moving forward. So, maglipase, I think that's a very promising area.
01:00:00.000 --> 01:00:31.000
And then there's also, we mentioned the fatty acid binding proteins, those little shuttles. There's some inhibitors now that are in clinical trials also based on strong preclinical mouse studies. They found the right indications and they're treating these patients with these inhibitors of fatty acid binding proteins and boosting the endocannabinoids. The endocannabinoids often are I like to call them the help me signal or the repair signal.
01:00:32.000 --> 01:00:51.000
They're produced when you need to slow down things and things. And therefore that's the way I think about it in the therapeutic approach is what you're doing is you're boosting the
endocannabinoids and therefore you're boosting the help me signal and you're helping your body to deal with the disease.
01:00:54.000 --> 01:01:06.000
Oftentimes, the nervous system gets the most attention when we talk about endogenous cannabinoids. But of course, these things are used elsewhere. They're used in the immune system. They're used outside the nervous system in a bunch of tissue systems.
01:01:06.000 --> 01:01:31.000
What are some of the bigger examples that help us understand what this system of regulation is doing outside of the nervous system. Why do we have these receptors and these endocannabinoids in various different cell and tissue types? And what does that sort of tell us about the core function? I think you were kind of just starting to allude to it a little bit, but can you maybe give some examples of say immune system regulation by endocannabinoids or somewhere else to help illustrate this?
01:01:33.000 --> 01:02:09.000
Absolutely, so it is true that the cannabinoid receptors are expressed by multiple cells in the peripheral tissue. I would say that if we start with the cannabinoid CB1 receptor, the level of expression of those CB1 receptors is much lower in those other cells in the periphery compared to neurons. So when we think about THC, we know that when you take THC, there's gonna be some psychotropic effects. And THC will also modulate some physiological responses in the periphery.
01:02:09.000 --> 01:02:55.000
Immune cells is one, vasculature, blood pressure is another one, which is why individual have red eyes when they're high, because there's a hypotension and therefore dilation of the blood vessels. There's quite a bit of cannabinoid receptors in the liver, and they're really involved in liver metabolism, which is why there's this really interesting inverse correlation between the individuals that take cannabinoids, THC and actually lose weight, and they eat more. They take THC, they have the munchies, and actually they do not gain weight. There's this dichotomy.
01:02:56.000 --> 01:03:21.000
It's because those CB1 receptor in the liver, for example, are going to regulate liver metabolism and energy expenditure and metabolism. So the liver, here is one organ that doesn't have cannabinoid receptor is the kidney. The muscle also doesn't really have, the heart doesn't really have many CB1 receptor. Good thing, right?
01:03:21.000 --> 01:03:38.000
We're not gonna die from a heart attack. The immune system is fascinating because, so one of the function of the CB1 receptor that we mentioned, so in neurons it regulates neurotransmitter release, okay. and their phenotype. What do they look like?
01:03:38.000 --> 01:04:26.000
In immune cells, it's a little bit the same also. You have those CB1 receptors that are going to regulate the immune cell transmission, their ability to release immune molecule, those fatty acids we talked about, those prostaglandins, some cytokines, And here, the CB2 receptors are also very dominant. So, immune cells have both CB1 and CB2 receptor. And therefore, the endocannabinoid really regulates tightly the immune system, not only by regulating their phenotype, what kind of cytokines, the release, they even regulate how they It's called phagocytosis, how they gobble up those bugs when they're fighting those infections.
01:04:26.000 --> 01:04:52.000
They regulate how the immune cells travel in the body. That's similar into neurons, developing neurons. They're involved. So they'd have these really fun, and they regulate, I don't know, actually Giovanni, should check out if immune cells have CB1 receptors in their mitochondria, because that would be fascinating, because we know mitochondria are so important for immune responses, you need the energy.
01:04:53.000 --> 01:05:34.000
So truly, endocannabinoids have this fundamental function. They regulate cellular function at multiple levels, somewhat similarly between cell types, proliferation, migration. Selectivity of functions, neuron, neurotransmitter, they have a lot of CB1 receptors. So yes, that opens up actually a new question and there's an entire field there, which is, do we have, there's many diseases in the periphery, that can we actually develop therapeutics that are targeting the endocannabinoid signaling system and can help with those diseases.
01:05:35.000 --> 01:06:14.000
Liver, you know, cirrhosis or things like that. Immune, autoimmune disease, that's how I started. working on neuroinflammation when I started my lab is because patients that have multiple sclerosis, they back in the 90s that was the one of the diseases that was the most reported beneficial effect of cannabis use was the patients with multiple sclerosis. And therefore, that's how I started thinking, well, maybe it regulates the immune system, it dampens, because multiple sclerosis is an autoimmune disease.
01:06:15.000 --> 01:06:28.000
The disease is too strong and therefore let's try to dampen it. And that was the idea. Let's try to target the endocannabinoid system, CB1, CB2, to calm these immune cells in those dramatic autoimmune diseases.
01:06:29.000 --> 01:06:48.000
And we've talked about how these endocannabinoids are deployed in a activity-dependent manner. They're made on demand. They're regulated in a way that you can use it at this synapse over here when it's needed, but not the synapse over here. And so there's this really nice spatial and temporal regulation, this on-demand regulation of when these things get deployed.
01:06:49.000 --> 01:07:22.000
At the same time, we've talked about things like FAA inhibitors, inhibiting these enzymes, which sort of determine the rate at which these signals are broken down. So even though there's this kind of point-to-point regulation and this very dynamic regulation of endocannabinoid signaling, there's also sort of just a background level or background tone that we can talk about. Endocannabinoid tone is a concept that sometimes you hear people talk
about. What is that and how much does the overall tone of endocannabinoids differ moment to moment in an individual or between, say, two individuals in a population?
01:07:23.000 --> 01:08:00.000
So while we know much more about on and off production of endocannabinoids because that's where neuroscience pay attention and how does it regulate neurotransmission, we know much less about the endocannabinoid tone. The way to think about it is that it's going to have a very different biological function. Endocannabinoids are produced in an activity-dependent manner, and they're gonna regulate the cellular function over a small amount of time. I'm gonna shut off this neuron for a while, because it's too active.
01:08:01.000 --> 01:08:34.000
whereas the endocannabinoid tone is going to tonically activate those receptors and therefore really change. So, it's really, I think the only difference is basically the temporal activation of the cannabinoid receptor. Does our physiology want it on and off because we need to regulate neurotransmission now? Or are we going to regulate the tone and therefore change the overall phenotype of the neurons on a longer term?
01:08:34.000 --> 01:09:07.000
I'm gonna activate these receptors maybe on the cell soma directly. So for example, there's a really fascinating, again, another, function of endocannabinoids to help the brain, for example. So when you activate those CB1 receptors that we talked about on the main neurons, not the presynaptic, just on the cell body, they go and they change the phenotype, they change gene expression. One of the genes that they actually upregulate is brain-derived growth factors, BDNS.
01:09:08.000 --> 01:09:50.000
That's very valuable for the health of the brain. So here's actually one situation where you would imagine, although it's not been demonstrated, but if you put the building blocks together, that's the most likely hypothesis is, for example, a higher tone, of endocannabinoids will activate more CB1 receptors on neuron cell soma and therefore have more BDNF and faster neuronal connectivity and things like that. So that would be one biological function that would separate the tone of endocannabinoid versus the on-off and I regulate neurotransmission.
01:09:50.000 --> 01:10:11.000
The tone probably regulates much more the phenotype of the neuron over a long term. And that's where the concept that you were referring to changing our diet. Right? I would imagine that changing the diet will have an effect predominantly actually on the tone.
01:10:11.000 --> 01:10:22.000
And you might have more endocannabinoids and maybe a healthier brain. This is all me putting pieces together. We've never proven this, but it'd be a cool experiment to test.
01:10:22.000 --> 01:10:38.000
Yeah. Yeah. Yeah. So like at any given moment, of course, like there's going to be highly dynamic changes that are highly context dependent in where endocannabinoids are being deployed and how many are being used, but that's all sort of riding on top of this general background tone that we're talking about.
01:10:38.000 --> 01:10:51.000
And you're saying that perhaps it's not proven, but perhaps, you know, changes in diet and things like that might slowly change that background level of tone over time. But on top of that, you're always going to have these sort of bigger, faster changes that are more
01:10:52.000 --> 01:11:19.000
uh dynamically regulated correct and you know the parallel is dopamine dopamine that has also a phasic activation and then a tonic activation and those two things actually do different things on the on the dopaminergic receptor so i think this is a a concept or a mechanism that biology uses quite often. Am I going to produce this neurotransmitter for a long time or just on and off? Probably both.
01:11:20.000 --> 01:11:22.000
Yeah. Yeah. Because they have different functions.
01:11:22.000 --> 01:11:27.000
Right. Right. You can use the same signaling molecules, the same items.
01:11:27.000 --> 01:11:27.000
Absolutely.
01:11:28.000 --> 01:12:08.000
And you can change how they function or what they do by playing with either a slower timescale or a faster timescale changes in the signal. Yeah. So just based on your knowledge as a basic researcher and what we know generally about endocannabinoid signaling and all of the complexities involved, what's your general take on the rise in THC consumption, exogenous cannabinoids that we've seen for a number of years now. I forget some of the exact statistics and stuff, but we know that cannabis use is up at least in certain some populations.
01:12:08.000 --> 01:12:26.000
I believe some populations are now consuming cannabis more often or more overall than even alcohol. What are the pros and cons here, both in terms of the overall amount people are using and also sort of the differences between adults and younger individuals?
01:12:27.000 --> 01:12:42.000
Absolutely. So that's a really good question. And there's a lot to say about this. I was actually involved in the task force to implement I-502, the legalization of cannabis in Washington state.
01:12:43.000 --> 01:13:29.000
And so I was able to actually be really in the field, understanding how new legislation is actually put together. The biggest aspect to think about are, there's several aspects, and we need to differentiate THC versus CBD. I'm not sure if we wanna go after CBD, but if we focus on Delta-9 tetrahydrocannabinol, THC, The first thing to consider is the age of consumption. And because we know, there's actually really no doubt that there is a vulnerable population, a subset of adolescents that are very vulnerable to using cannabis during adolescence.
01:13:30.000 --> 01:14:01.000
Now the question always becomes how much and how often? because everything at very high dose and all the time will actually be bad on your body, especially THC. So the fact there, there's either a legal system, you make it illegal for adolescents, that's one
way to think about it, absolutely. The other way is to educate adolescents and let them understand that this is actually detrimental for their development.
01:14:02.000 --> 01:14:27.000
The good news is that there's actually an age where the detrimental effect is not as strong. I would say after 25 years old, when your brain is fully developed, then people start using cannabis and there's less impact on brain development because the brain is already developed. And maybe there, there might actually have some positive effects. It might reduce stress levels a little bit.
01:14:28.000 --> 01:14:55.000
It might temper inflammation sometimes, help you sleep for some individuals. So there's really a period during development where we know it's gonna be bad for the brain, and then a period where we can actually start thinking about good regimen, how much am I gonna take, how often, and that might become medical. So that's one aspect, the regimen and how much. And now we can get into the products.
01:14:57.000 --> 01:15:13.000
the cannabis-based products. So what has happened, oh yes, that's right, because you also interviewed Ryan Vandrie for the PK. That is excellent. And he's asking very important questions.
01:15:13.000 --> 01:15:36.000
So depending on the product, are you going to smoke it and therefore it's going to go into your brain on and off very quickly? Are you going to only smoke a joint or are you actually going to dab? 35% THC versus 95% THC. Plus dabbing is going to go up and down very quickly into your brain.
01:15:37.000 --> 01:16:06.000
That is the one first criteria that will increase the likelihood of getting addicted to a drug. If your dopamine goes up fast, up nicotine, up and down very quickly. So dabbing THC, high concentration of THC very quickly will induce a very high increase in dopamine and their potential addiction, cannabis use disorder.
01:16:06.000 --> 01:16:27.000
Yeah. And let's define and talk about that just a little bit for people because it's important and there are very different viewpoints and biases that people have out there. When I worked in the marijuana industry, this was a very polarizing subject and very difficult to address because some people would insist You know, cannabis is not addictive. It's not addictive like other drugs.
01:16:27.000 --> 01:16:45.000
And some people would say, well, yes, it is. It is habit forming addiction dependency, habit forming. Like, what do these terms mean to you? And from your perspective, you know, is what is the habit, habit forming potential of THC in particular relative to other drugs that we can talk about?
01:16:48.000 --> 01:17:02.000
So the first thing is that both are right. It is true that some people get addicted and it's true that some people don't get addicted. Thus the concept of vulnerable population. Some people are more vulnerable to drug addiction than other ones.
01:17:03.000 --> 01:17:22.000
The precise reason why they're more vulnerable is something that the field is working on. Genotyping, is there a genetic, makeup that makes this poor individual more likely to become addicted or not. So I think both are right. I think some people get addicted and some people don't.
01:17:24.000 --> 01:17:46.000
What is the term of addiction in the field of cannabis? It's related to cannabis use disorder. So in the DSM-5 now, there's some criteria. It's basically a new disease, a new syndrome that has been discovered because of the rise in the consumption of products that are very potent in THC.
01:17:47.000 --> 01:18:10.000
The more potent, The more you consume, the more likely you're going to have the cannabis use disorder. Within the cannabis use disorder, there's multiple criteria that the patient needs to have to be considered having cannabis use disorder. One is not being able to stop. That's the definition of addiction.
01:18:11.000 --> 01:18:31.000
Even though I know that it's not good for me, I'd rather continue smoking. That would be one criteria. How addictive is it compared to other drugs? It comes back to how much dopamine is produced in the brain and how quickly.
01:18:32.000 --> 01:18:52.000
So nicotine is super addictive because you have a very quick rise. Cocaine is super addictive because you have a big rise. THC is more and more addictive. as you start using the DABs, for example, because now you have 95% of THC on and off.
01:18:53.000 --> 01:19:02.000
So that's how I think about it. It's really the amount of THC, how often, and only of a sub-population, a vulnerable population.
01:19:02.000 --> 01:19:18.000
Yeah. And I think it's worth dwelling on and really emphasizing this idea of vulnerability in discrete subpopulations, because it really is true. I've done a couple episodes with Christian Lucher, who does excellent work here. And just to give people a sense for this, you can give rats cocaine.
01:19:19.000 --> 01:19:44.000
And some of them get addicted, but some of them don't. And it's actually, it's not just a random subsample. For reasons that are still somewhat mysterious, there are discrete subsamples of individuals, whether it's rats or humans, that are just more prone to addiction to virtually anything, it seems in some cases, than others. So it's not that Everyone becomes addicted if you consume enough or no one becomes addicted because it's a non addictive substance.
01:19:44.000 --> 01:19:54.000
It can be that if you consume enough and on top of that, you're this sensitive individual rather than someone else, you can develop dependence or something like that.
01:19:55.000 --> 01:20:11.000
Absolutely. And the fact that we actually see that in the preclinical rodents and rats is actually a power for us to understand what is the difference because we can actually do some gene sequencing and try to understand that.
01:20:11.000 --> 01:20:31.000
What's kind of fascinating about that work is in rats and in people, the numbers kind of shake out the same. It's like something like
roughly one in five rats will become addicted to cocaine if you just give them a bunch of cocaine over and over again and nothing else to do. So it's like one in five. But why that 20% and not the other 80%, nobody knows.
01:20:31.000 --> 01:20:42.000
But it turns out that the numbers are kind of similar in humans too. It's like this one in five-ish percentage of the population for that substance. at least, that's sensitive. And is it a birth order thing?
01:20:42.000 --> 01:20:45.000
Is it the way you grow up? I don't think anyone really knows yet, but...
01:20:45.000 --> 01:20:52.000
I would say, I would argue it's probably really fundamental biology because rats in a lab are so similar.
01:20:52.000 --> 01:20:53.000
Right, right.
01:20:53.000 --> 01:20:59.000
And then we have exactly the same thing in this really diverse population of humans. So it's probably something very fundamental.
01:20:59.000 --> 01:21:08.000
Yeah. Christian Lucher had the same intuition because that is a huge difference. These rats are almost genetically identical, but humans obviously aren't. So I don't know what the answer is.
01:21:08.000 --> 01:21:18.000
I think he's working on some hypotheses that have to do with birth order and how much of the nutrition you get early in life as the last pup born or whatever, but TBD on that.
01:21:19.000 --> 01:21:25.000
Yeah, I'm excited. He's an excellent scientist. I can't wait to see what happens.
01:21:25.000 --> 01:21:35.000
So what are some of the things that you're working on today or that just the field in general is working on maybe using some of these new sensors that you think are going to produce some exciting new insights relatively soon in the future?
01:21:37.000 --> 01:22:17.000
Well, yes, so one of the biological questions that we're testing in my lab is really to try to better understand the effect of THC on mouse behavior. So we have a couple of papers coming out now that have been accepted. One, I'm excited, coming out in Nature, that actually will describe multiple things. The first thing is that we actually studied a very specific behavior in the mouse, which is the mouse approaching a sucrose bottle so that it's a reward.
01:22:17.000 --> 01:22:58.000
So the mouse is very excited, it comes close to the sucrose bottle and sips a little bit of sucrose and that's a reward. And you can actually train the mouse in the Pavlovian reward training so they get actually excited by the reward coming up because there's a little light that opens up. So what actually drives this behavior, which is really fundamental, especially if you think about reward and addiction, how can we understand this behavior? So we actually looked at the endocannabinoid signaling system in specific brain areas in the thalamus that projects to actually the nucleus accumbens in the brain.
01:22:58.000 --> 01:23:32.000
The nucleus accumbens is really an area of the brain that's involved in drug addiction. And what we discovered is that these neurotransmitters that go from the thalamus and project to the nucleus accumbens, the neurotransmitter release of those is regulated by endocannabinoids, also CB1 receptors. So, we actually discovered a new function for the endocannabinoid signaling system in REWARD, which is to simply control the approach and going after. So, that's the first part that we discovered.
01:23:32.000 --> 01:24:01.000
How did we discover that? We developed a machine learning pose estimation algorithm. So in this time of AI computing, I love new technology. So we got really interested in monitoring those little mice in the linear track and tracking them, just like when you do, uh, facial recognition, where you know where the eyes are.
01:24:01.000 --> 01:24:16.000
We have little dots on the mice, on the tail, on the nose, and we look at them as they travel in this linear track. They walk, they stop, they groom, they rear, they explore. It's fascinating. And then there's the sipper, and they go and they sip.
01:24:17.000 --> 01:24:37.000
the sucrose. So we can actually, with a video camera, monitor these mice, and then with this AI machine learning approach, basically analyze what they're doing. And we can say exactly how quickly it approaches the bottle of sucrose, how quickly it disengages, and all of these behaviors. I see.
01:24:37.000 --> 01:24:57.000
So using these types of tools, you can start to ask questions like, OK, if we put a bunch of mice in the chamber, they might all approach the sugar water sometimes, but some do it more often. Some do it more quickly. Some are more interested in doing other things. And you can sort of ask, how do things like endocannabinoid levels relate to those individual differences?
01:24:57.000 --> 01:25:25.000
Correct. So the way we know that is now we can actually add those sensors that I talked about in these mouse brain, specifically, for example, in the thalamus, that brain that I talked about, or the nucleus accumbens, and look at how these endocannabinoids are produced. in an activity-dependent manner. And it turns out that as the mouse approaches the sucrose bottle, there's these endocannabinoids that are produced for a couple seconds.
01:25:25.000 --> 01:26:16.000
And the idea, and that was another part that we kind of did in the paper by electrophysiology, is that these endocannabinoids in this brain area are going to activate those CB1 receptors. with specific dynamics and regulate neurotransmitter release, reduce a little bit of the GABA transmission, reduce a little bit of the glutamate, and that will participate in the neuronal network that will control this behavior of approach. So that was the punchline of this paper, is really discovering the fundamental function of, in this case, it's 2-AG, the second endocannabinoids that's mainly produced, one new function of 2AG in the brain, which is to actually control reward approach. And that obviously brings up a new question.
01:26:17.000 --> 01:26:29.000
Can we use
this new understanding to develop therapeutics for drug addiction or for cannabis use disorder? Now that we know that these endocannabinoids are produced there at that moment.
01:26:30.000 --> 01:26:53.000
Yeah. And so it's just worth emphasizing the tools you're talking about. So you not only have the machine learning based video tracking tools that allow you to quantify and record what the animal is doing at the overall behavioral level, but some of these new sensors are allowing you to very specifically record endocannabinoid dynamics, how quickly our endocannabinoid level is going up and down in particular parts in the brain.
01:26:53.000 --> 01:26:58.000
So you're not just looking at some sort of very, very fuzzy high level signal, you're actually getting quite specific with this.
01:26:59.000 --> 01:27:22.000
and very temporally specific in a very time dependent. And at the same time, we're also measuring neuronal activity. So like that, we can actually connect what we talked about. Ah, there's more neuronal activity, there's probably more calcium, and therefore more endocannabinoids that are produced that are going to regulate those CB1 receptors on nearby neurons.
01:27:23.000 --> 01:27:42.000
What... So, exogenous cannabinoids have powerful effects, endogenous cannabinoids have powerful effects. They're tapping into this sort of homeostatic regulation that's really fundamental. And this is why cannabinoids have so many different effects.
01:27:45.000 --> 01:28:04.000
side effects of THC, as we mentioned earlier, is the munchies, right? Animals tend to get hungry, they eat more. And yet, there's this interesting and seemingly paradoxical situation that you mentioned earlier, where, yes, they stimulate feeding behavior in the munchies, but long-term THC users tend to have lower BMIs, lower body weight. So what's going on there?
01:28:04.000 --> 01:28:29.000
Well, that might connect to something that I also think is interesting, which is that There used to be, for a little while in Europe at least, this CB1 receptor-based therapy for obesity, basically. It was a drug called remanubant, which antagonized the CB1 receptor and caused people to eat less. This was before GLP-1s were developed. You've probably never heard of remanubant, most of you, because it got pulled from the market.
01:28:30.000 --> 01:28:38.000
What was the remanubant story and what does that sort of tell us about how powerful things like the CB1 receptor actually are and how difficult it is to play with them?
01:28:39.000 --> 01:29:10.000
Yeah, the hypothesis there was very simple back then, Sanofi Pharmaceuticals in France. The idea was, well, if THC is an agonist that CB1 receptors and produces munchies, we're going to do an antagonist and it's going to block the munchies. And therefore, that was rimonabun or SR1 that people talk about in the field. And that molecule actually went all the way to being accepted in Europe.
01:29:10.000 --> 01:29:13.000
So, it passed all the clinical trials, the safety.
01:29:14.000 --> 01:29:16.000
But it actually made people eat less.
01:29:17.000 --> 01:29:29.000
It actually made people eat less. You would be on this drug and you would show the patient a cookie and they wouldn't eat it. Like, when does that happen? you know, only when your CB1 receptors are blocked.
01:29:29.000 --> 01:29:45.000
So then it's accepted. And then what happens, you know, when you do a phase three, you have thousands of people. And then when it's accepted, now you have hundreds of thousands of people. And therefore the likelihood of identifying a side effect is increased because more people are using it.
01:29:46.000 --> 01:29:58.000
And what happened, and actually it didn't happen right away. It happened after a couple of years, if I remember well. Some patients were getting depressed. because actually CB1 receptor controls mood.
01:29:59.000 --> 01:30:51.000
And therefore, if you break the CB1 receptor, you don't have the, you know, the reward aspect of going after your cookie, you might actually become more depressed. That would be to the point. Some patients were so depressed that they committed suicide. And that's when I think it was like after the third or fourth suicide, then they took the drug out of the market, because the side effect is too dramatic if people make, and that shut down so many drug development projects, trying to target the CB1 receptor in the brain for society to stop eating. But then what happened is the field continued to work. And then what we discovered is the CB1 receptors on the liver. and the CB1 receptors on the liver are the ones that regulate metabolism.
01:30:53.000 --> 01:31:22.000
Obesity, and therefore now there's a very simple trick that you can do in drug discovery is make a CB1 antagonist that does not go to the brain. That's very easy. You put a molecule and then it won't pass the blood-brain barrier. So now you're avoiding the depression, the suicide, because you're not targeting the CB1 receptors in the brain, but you're still targeting the CB1 receptors on your liver, that actually controls metabolism.
01:31:22.000 --> 01:31:24.000
So that's where the field is at.
01:31:24.000 --> 01:31:25.000
Have people actually done that?
01:31:25.000 --> 01:31:34.000
Yeah, that's happening right now. There's some molecules that are getting closer to human clinical trials, and those CB1 receptors do not pass the blood-brain barrier.
01:31:34.000 --> 01:31:44.000
So we've tested those in animals, CB1 antagonists that do not cross the blood-brain barrier. Correct. And what is the basic overall effect in those animals?
01:31:44.000 --> 01:31:47.000
Well, they eat less. They eat less, absolutely.
01:31:47.000 --> 01:31:56.000
So you get a similar Ramanubandh-like effect in terms of eating less, but they don't show any indications of anxiety or depression-like behavior. Correct.
01:31:56.000 --> 01:32:10.000
Okay. And actually, this is a field that I follow on the sides
only. Because then the question is, I understand how if you activate CB1 receptors on the liver, you're gonna change metabolism. Okay, that's fine.
01:32:10.000 --> 01:32:21.000
How I'm gonna digest food. But what about the... the motivation to get that cookie. Is it really only the CB1 receptors in the brain?
01:32:21.000 --> 01:33:02.000
Well, no, there's actually some research that shows that when you get hungry, there's actually another one of those lipid signaling molecules that is produced by the liver or the digestive system, goes into the blood. It's a lipid, it passes the blood-brain barrier, goes to your brain, activates its own receptors and say, go eat. So now the CB1 receptor antagonists that are peripherally restricted, they regulate the metabolism in the liver. But at the same time, those lipids can still go to the brain and tell you, oh, go ahead and eat.
01:33:02.000 --> 01:33:07.000
What are those lipids? Oh, I forgot what they are, but they're also signaling lipids. Yeah.
01:33:07.000 --> 01:33:20.000
Yeah. Signaling lipids, not unlike cannabinoids, but they're different ones. They're made in the liver. They go through the bloodstream and they actually pass the blood-brain barrier and they can affect motivation to eat, even though the signal arises in the liver.
01:33:20.000 --> 01:33:30.000
Fascinating. Absolutely. Wow. So as a cannabinoid biologist, knowing the history here with remanubant and how cannabinoids work, we've got the GLP-1s now.
01:33:31.000 --> 01:33:57.000
Lots of people are using them at this point. We're coming out with new versions basically every month, it seems. So this is going to be a huge area of growth, both in terms of the number of people using them, but also the diversity of the specific versions coming out. Are there any things that we should look out for as we go into the second, third, fourth, fifth year of people using GLP-1s in terms of them potentially having effects on mood and on motivation akin to what the cannabinoid-based drugs did in the past?
01:33:57.000 --> 01:34:02.000
Or are they likely working in such a different way that those types of side effects are unlikely to be seen?
01:34:04.000 --> 01:34:30.000
I think they're working in a very different mechanism and therefore the results are going to be very different. I think those GOP1 field is fantastic. It's so interesting and it has a lot of potential indication. We started with obesity and food intake, but actually it turns out that that might be also potential beneficial for some addictive drugs like nicotine and ethanol.
01:34:30.000 --> 01:35:11.000
So, it has that parallel with the cannabinoid signaling system that it regulates food intake and reward. But I think they're going to be, because the receptors are very different, because the receptors are expressed in different parts of the brain compared to the CB1 receptor, I think the GLP-1 drugs are going to be having different effects. And plus, it's only the beginning of this
entire field. Now they're optimizing, like every field in medicine, transformative, it always starts and then we have a little bit of toxicity and then we optimize and we can actually develop a completely different therapeutic approach.
01:35:11.000 --> 01:35:44.000
One thing that I've, this is anecdotal, but I thought it was fascinating. So anecdotal, N equal one, this individual in California was taking GLP-1 drugs to lose weight. And then it's the birthday of their kid, and there's a beautiful cake, and they want to eat the cake of their birthday, and they don't have the motivation at all. And that individual actually used cannabis, got the munchies, and was able to actually enjoy the cake.
01:35:45.000 --> 01:35:57.000
So that to me is fascinating because it really tells me that those signaling system are actually very different and might be, you know, it's just an interesting tidbit. I'm not sure. Yeah. Yeah.
01:35:57.000 --> 01:36:05.000
Because the person wants to eat the cake. They want to lose weight, obviously, but they want to participate in the ritual of the birthday.
01:36:05.000 --> 01:36:06.000
That one day is okay.
01:36:06.000 --> 01:36:11.000
Yeah. So you might have a temporary tool, in this case, cannabis. Exactly. An exit.
01:36:13.000 --> 01:36:35.000
So what do you want people to know? What do you want people to take away about cannabinoids, generally speaking? And I'll let you decide what you want to say. Endogenous cannabinoids, THC and exogenous cannabinoids, but what's something that you want to really emphasize or reiterate from people related to the biology that we discussed today that are listening and that are interested in cannabinoid-based therapies or substances of any kind?
01:36:36.000 --> 01:37:10.000
Absolutely. I think the field has come a very long way and that's 20, well, a couple of things. The first thing is when I started studying the cannabinoids 25 years ago, signaling system, I spent a lot of my time explaining to people that it has some medical properties and not only the high, the psychotropic effect. Now the field has recognized and understood that cannabis has medical properties.
01:37:11.000 --> 01:37:36.000
And I spend quite a bit of time telling people that it's not gonna cure everything. It's gonna be very specific. So that's one thing that I think I'd like people to understand is that cannabis, we used to talk about it as the drug for the potheads. You wanna smoke out and watch a movie and things like that, that's fine, or mind altering.
01:37:37.000 --> 01:38:06.000
That's one way to think about it. But I think the future, we will maybe even forget that aspect and talk about cannabis as a transformative medicine. Because it was that the research that we are doing right now resulted in medicines that are beneficial or might even cure some diseases where we had nothing. The first example that comes to mind is the epilepsy field with the Dravet syndrome.
01:38:07.000 --> 01:38:33.000
When cannabidiol was accepted by the FDA, that was a landmark, because these poor little kids, they have really pretty much nothing to help with those seizures. And then you have the CBD that transform a little young girl that has hundreds of seizures per week to only a couple seizures per week. That's a life-changing experience. So I think we're at the very beginning.
01:38:33.000 --> 01:39:01.000
And I've been in the field for so many years that I've seen it evolved. And the beginning was, okay, let's figure out the receptors, okay? And then let's figure out the enzymes, okay? And now where we're at is small molecules in clinical trials that are very promising for specific diseases, which is why I think the cannabinoid field is gonna generate some transformative new medicines that gonna help people.
01:39:03.000 --> 01:39:05.000
All right, Professor Nefi Stella, thank you very much for your time.
01:39:06.000 --> 01:39:10.000
That was great, thank you.
01:39:16.000 --> 01:39:43.000
A great way to support my efforts is to visit my support page at mindandmatter.substack.com. A link to that page is in the episode description, or you can search for it on the Substack page itself. The support page has an up-to-date list of my affiliate partners. These are companies I work with, and if you buy those products through those links or using the discount codes provided, Those will get you a great deal on a variety of products related to optimizing physical, metabolic, or mental health and vitality.
01:39:43.000 --> 01:40:11.000
These are all products I use myself and some of them are directly related to podcast episodes or formulated by Minded Matter guests. For example, there's a great product called Keto Citra formulated by a kidney biologist who is on episode number 186. It contains the ketone body BHB together with several minerals in a precise ratio formulated with kidney health in mind. also links to products like physical technology devices to track your metabolic health, digital applications to help you find and learn about food and consumer products, and more.
01:40:12.000 --> 01:40:30.000
One product I use every day is the AquaTrue water filter. I recommend this to everyone because it gets everything out of your drinking water, heavy metals, microbes, endocrine disruptors, microplastics, you name it. Other charcoal or gravity-based filters that a lot of people use don't get everything out, they just get some of the stuff out. So I really like the AquaTrue product.
01:40:30.000 --> 01:40:40.000
You can look for a link to my affiliate partners on my support page or directly in the episode description to this episode, or you can go to mindandmatter.substack.com to find it there.